Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
6.64
-0.03 (-0.38%)
At close: Nov 3, 2025, 4:00 PM EST
6.70
+0.07 (0.98%)
After-hours: Nov 3, 2025, 4:10 PM EST
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change (1Y)
5
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,468,348
Market Cap
152.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACTU News
- 6 weeks ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire
- 7 weeks ago - Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 3 months ago - Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial - GlobeNewsWire
- 4 months ago - Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewsWire